Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists
Age ≥ 18 years old
Patients must have adequate laboratory values
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Ability to swallow capsules or tablets
You may not be if
Patients with active central nervous system (CNS) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months.
Patients with a second primary malignancy that is currently clinically significant or requiring active intervention
Impaired heart function or clinically significant heart disease
Impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of LBH589
Ongoing diarrhea
Liver or renal disease with impaired hepatic or renal functions
Concomitant use of any anti-cancer therapy or certain drugs
Female patients who are pregnant or breast feeding
Patients not willing to use an effective method of birth control
Clareo Health | A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
